<DOC>
	<DOCNO>NCT01955174</DOCNO>
	<brief_summary>This study aim evaluate efficacy safety endoscopic injection 100 IU botulinum toxin ( BTX ) distal esophagus patient symptom relate hypercontractile esophageal motility disorder .</brief_summary>
	<brief_title>Botulinum Toxin Injection Hypercontractile Esophagus</brief_title>
	<detailed_description>Eligible patient present chest pain and/or dysphagia relate follow hypercontractile esophageal motility disorder : distal esophageal spasm , jackhammer esophagus , nutcracker esophagus type III achalasia normalization integrate relaxation pressure treatment , base Chicago classification esophageal motility disorder high resolution manometry ( HRM ) . Upper gastrointestinal endoscopy barium swallow perform BTX injection eliminate secondary disorder . This prospective , randomize , double blind , control trial compare BTX injection sham procedure ( absence injection , clinical team perform follow-up aware result randomization ) . Drugs could affect esophageal motility ( nitrates calcium channel blocker ) stop study . Included patient undergo esophageal endoscopic ultrasound examination ( EEUS ) upper gastrointestinal endoscopy general anesthesia . In absence contraindication , patient randomize two arm : BTX injection injection . The active treatment group receive 100 unit type A BTX ( BotoxÂ® , Allergan ) dilute 10 mL saline serum ; BTX inject low third esophageal wall 10 site 2 10 cm squamo-columnar junction . The control arm receive injection EEUS upper GI endoscopy ( sham procedure ) . Clinical response assess base evolution Eckardt score , quality life score ( Gastrointestinal Quality Life Index ( GIQLI ) , weight gain . A significant clinical response define Eckardt score &lt; 3 ( together individual score &lt; 2 ) . Manometry pattern compare procedure . Safety monitor base occurrence chest pain score Likert scale occurrence adverse event . Follow-up clinical evaluation perform 1 2 month procedure . A second esophageal HRM realize 3 month procedure , follow endoscopic BTX injection case non-response two monthly visit . Follow-up visit do 6 12 month first procedure . An additional HRM perform 12 month .</detailed_description>
	<mesh_term>Esophageal Motility Disorders</mesh_term>
	<mesh_term>Esophageal Spasm , Diffuse</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patient noncardiac chest pain and/or dysphagia global Eckardt score strictly 3 point equal 3 `` chest pain `` `` dysphagia `` Hypercontractile esophagus normal esogastric junction relaxation base Chicago classification high resolution manometry Man woman 18year old old Normal upper gastrointestinal endoscopy within one year inclusion Barium swallow without argument external compression Effective form birth control ( applicable ) Signed write informed consent form voluntarily Patient health insurance Man woman 18year old Past history esogastric surgery Evolutive cancer coagulation disorder Absence effective form birth control ( applicable ) Pregnant woman woman plan become pregnant expected length study Breastfeeding woman Allergy botulinum toxin excipients Myasthenia Aminoglycoside treatment Endoscopic contraindication prior study Endoscopic contraindication study Psychiatric addictive disease could affect compliance constraint study Patient refuse participate study Language barrier limit understand study Incapability give consent Concomitant participation another research study No write consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Botulinum toxin</keyword>
	<keyword>Esophageal motility disorder</keyword>
	<keyword>Distal esophageal spasm</keyword>
</DOC>